Posted by Michael Wonder on 17 Sep 2016
New treatment for breast cancer
16 September 2016 - Ibrance provides novel treatment option for women with advanced or metastatic disease.
The EMA has recommended granting a marketing authorisation in the European Union for Ibrance for the treatment of women with locally advanced or metastatic breast cancer. It is to be used for cancer that is hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative.
